Experienced in WT1-Related Wilms Tumor Syndromes

Dr. Paul Sieber

Urology
UPMC
Keystone Urology Specialists
2106 Harrisburg Pike, Suite 200, 
Lancaster, PA 
On Staff At
Clinical Trials:Currently Recruiting for 1 Trial

Experienced in WT1-Related Wilms Tumor Syndromes
UPMC
Keystone Urology Specialists
2106 Harrisburg Pike, Suite 200, 
Lancaster, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Paul Sieber is an Urologist in Lancaster, Pennsylvania. Dr. Sieber is rated as an Experienced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Non-Muscle Invasive Bladder Cancer, Orchiectomy, and Ureteroscopy.

His clinical research consists of co-authoring 33 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Indiana University School Of Medicine
Residency
Pennsylvania State University College of Medicine
Specialties
Urology
Licenses
Urology in PA
Board Certifications
Urology, 1990
Fellowships
Pennsylvania State University College of Medicine
Hospital Affiliations
Wellspan Good Samaritan Hospital
Upmc Lititz
Lancaster General Hospital
Penn State Health St. Joseph
Wellspan Ephrata Community Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Avalon Health Care
  • MEDICARE PDP
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Gateway Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER MEDICARE PART D
Geisinger
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Partners Plans
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
PA Health and Wellness
  • HMO
  • MANAGED MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

Keystone Urology Specialists
2106 Harrisburg Pike, Suite 200, Lancaster, PA 17601
Call: 717-393-1771
Other Locations
Keystone Urology Specialists
2110 Harrisburg Pike, Suite 1, Lancaster, PA 17601
Call: 717-393-1771
Keystone Urology Specialists
175 Martin Avenue, Suite 300, Ephrata, PA 17522
Call: 717-393-1771

Additional Areas of Focus

Dr. Sieber has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Prostate Cancer
Bladder Cancer
Kidney Stones
Testicular Cancer

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


8 Clinical Trials

An Open-Label, Phase 1/1b Study of ORIC-944 as a Single Agent or in Combination With an Androgen Receptor Pathway Inhibitor in Patients With Metastatic Prostate Cancer
An Open-Label, Phase 1/1b Study of ORIC-944 as a Single Agent or in Combination With an Androgen Receptor Pathway Inhibitor in Patients With Metastatic Prostate Cancer
Enrollment Status: Recruiting
Publish Date: August 11, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Randomized Controlled Trial of ProstAtak® as Adjuvant to Up-front Radiation Therapy For Localized Prostate Cancer
A Randomized Controlled Trial of ProstAtak® as Adjuvant to Up-front Radiation Therapy For Localized Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 30, 2025
Intervention Type: Biological
Study Drugs: Aglatimagene besadenovec, Valacyclovir
Study Phase: Phase 3
A Randomized Controlled Trial Of AdV-tk + Valacyclovir Administered During Active Surveillance For Newly Diagnosed Prostate Cancer
A Randomized Controlled Trial Of AdV-tk + Valacyclovir Administered During Active Surveillance For Newly Diagnosed Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 30, 2025
Intervention Type: Biological, Drug
Study Drugs: Aglatimagene Besadenovec, Valacyclovir
Study Phase: Phase 2
A Phase 2, Single Arm Study of CG0070 Combined With Pembrolizumab in Patients With Non Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)
A Phase 2, Single Arm Study of CG0070 Combined With Pembrolizumab in Patients With Non Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)
Enrollment Status: Completed
Publish Date: September 25, 2024
Intervention Type: Biological, Other
Study Drugs: Engineered Oncolytic Adenovirus, Pembrolizumab, N-Dodecyl-B-D-Maltoside
Study Phase: Phase 2
A Phase 2 Non-randomized Open-label Study Examining the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer (CRPC)
A Phase 2 Non-randomized Open-label Study Examining the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer (CRPC)
Enrollment Status: Terminated
Publish Date: June 21, 2024
Intervention Type: Drug
Study Phase: Phase 2
Development, Validation, and Dissemination of an Integrated Risk Prediction Model and Decision Aid to Discern Aggressive Versus Indolent Prostate Cancer
Development, Validation, and Dissemination of an Integrated Risk Prediction Model and Decision Aid to Discern Aggressive Versus Indolent Prostate Cancer
Enrollment Status: Completed
Publish Date: June 12, 2023
Intervention Type: Behavioral
Study Phase: Not Applicable
Long-Term Prospective Registry to Evaluate Treatment Decisions and Clinical Outcomes in Patients With Favorable Intermediate-Risk Localized Prostate Cancer Following Cell Cycle Progression (CCP) Testing (Prolaris® Test)
Long-Term Prospective Registry to Evaluate Treatment Decisions and Clinical Outcomes in Patients With Favorable Intermediate-Risk Localized Prostate Cancer Following Cell Cycle Progression (CCP) Testing (Prolaris® Test)
Enrollment Status: Terminated
Publish Date: June 23, 2022
Intervention Type: Diagnostic test
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Enrollment Status: Completed
Publish Date: May 11, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 7 Less Clinical Trials

33 Total Publications

Safety and Tolerability of Relugolix in Combination with Abiraterone or Apalutamide for Treatment of Patients with Advanced Prostate Cancer: Data from a 52-Week Clinical Trial.
Safety and Tolerability of Relugolix in Combination with Abiraterone or Apalutamide for Treatment of Patients with Advanced Prostate Cancer: Data from a 52-Week Clinical Trial.
Journal: Targeted oncology
Published: March 17, 2025
View All 33 Publications
Similar Doctors
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Robert G. Uzzo
Urology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Robert G. Uzzo
Urology

Temple Faculty Practice Plan Inc

3509 N Broad St, 
Philadelphia, PA 
 (63.9 miles away)
215-707-2111
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Robert Uzzo is an Urologist in Philadelphia, Pennsylvania. Dr. Uzzo is rated as an Elite provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Renal Cell Carcinoma (RCC), Muscle Invasive Bladder Cancer, Renal Oncocytoma, Nephrectomy, and Cystectomy.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Thomas J. Guzzo
Urology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Thomas J. Guzzo
Urology

Penn Urology Perelman

3400 Civic Center Boulevard, West Pavilion, 3rd Floor, 
Philadelphia, PA 
 (62.1 miles away)
215-662-2891
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Thomas Guzzo is an Urologist in Philadelphia, Pennsylvania. Dr. Guzzo is rated as an Elite provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Bladder Cancer, Prostate Cancer, Renal Cell Carcinoma (RCC), Nephrectomy, and Cystectomy. Dr. Guzzo is currently accepting new patients.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Michael W. Phelan
Urology | General Surgery
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Michael W. Phelan
Urology | General Surgery

University Of Maryland Surgical Associates PA

419 W Redwood St, Fl 3, 
Baltimore, MD 
 (55.7 miles away)
410-328-5300
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Michael Phelan is an Urologist and a General Surgeon in Baltimore, Maryland. Dr. Phelan is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, WT1-Related Wilms Tumor Syndromes, Nephrectomy, and Reconstructive Urology Surgery. Dr. Phelan is currently accepting new patients.

VIEW MORE WT1-RELATED WILMS TUMOR SYNDROMES DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sieber's expertise for a condition
ConditionClose
  • Elite
  • Prostate Cancer
    Dr. Sieber is
    Elite
    . Learn about Prostate Cancer.
    See more Prostate Cancer experts
  • Distinguished
  • Familial Prostate Cancer
    Dr. Sieber is
    Distinguished
    . Learn about Familial Prostate Cancer.
    See more Familial Prostate Cancer experts
  • Muscle Invasive Bladder Cancer
    Dr. Sieber is
    Distinguished
    . Learn about Muscle Invasive Bladder Cancer.
    See more Muscle Invasive Bladder Cancer experts
  • Non-Muscle Invasive Bladder Cancer
    Dr. Sieber is
    Distinguished
    . Learn about Non-Muscle Invasive Bladder Cancer.
    See more Non-Muscle Invasive Bladder Cancer experts
  • Urinary Tract Infection in Children
    Dr. Sieber is
    Distinguished
    . Learn about Urinary Tract Infection in Children.
    See more Urinary Tract Infection in Children experts
  • Advanced
  • Bilateral Hydronephrosis
    Dr. Sieber is
    Advanced
    . Learn about Bilateral Hydronephrosis.
    See more Bilateral Hydronephrosis experts
  • Bladder Cancer
    Dr. Sieber is
    Advanced
    . Learn about Bladder Cancer.
    See more Bladder Cancer experts
  • Boils
    Dr. Sieber is
    Advanced
    . Learn about Boils.
    See more Boils experts
  • Carbuncle
    Dr. Sieber is
    Advanced
    . Learn about Carbuncle.
    See more Carbuncle experts
  • Enlarged Prostate (BPH)
    Dr. Sieber is
    Advanced
    . Learn about Enlarged Prostate (BPH).
    See more Enlarged Prostate (BPH) experts
  • Folliculitis
    Dr. Sieber is
    Advanced
    . Learn about Folliculitis.
    See more Folliculitis experts
View All 16 Advanced Conditions
  • Experienced
  • Bladder Stones
    Dr. Sieber is
    Experienced
    . Learn about Bladder Stones.
    See more Bladder Stones experts
  • Chromophobe Renal Cell Carcinoma
    Dr. Sieber is
    Experienced
    . Learn about Chromophobe Renal Cell Carcinoma.
    See more Chromophobe Renal Cell Carcinoma experts
  • Clear Cell Sarcoma
    Dr. Sieber is
    Experienced
    . Learn about Clear Cell Sarcoma.
    See more Clear Cell Sarcoma experts
  • Empyema
    Dr. Sieber is
    Experienced
    . Learn about Empyema.
    See more Empyema experts
  • Erectile Dysfunction (ED)
    Dr. Sieber is
    Experienced
    . Learn about Erectile Dysfunction (ED).
    See more Erectile Dysfunction (ED) experts
  • Eunuchoidism Familial Hypogonadotropic
    Dr. Sieber is
    Experienced
    . Learn about Eunuchoidism Familial Hypogonadotropic.
    See more Eunuchoidism Familial Hypogonadotropic experts
View All 28 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2025 All Rights Reserved